Successful and Safe Reinstitution of Chemotherapy for Pancreatic Cancer after COVID-19

Cancer patients are regarded as highly vulnerable to severe acute respiratory syndrome coronavirus (SARS-CoV)-2. However, little is known regarding how cancer treatments should be restarted for cancer patients after coronavirus disease (COVID)-19. We herein report a pancreatic cancer case in which c...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagai, Kazumasa, Kitamura, Katsuya, Hirai, Yuji, Nutahara, Daisuke, Nakamura, Hironori, Taira, Junichi, Matsue, Yubu, Abe, Masakazu, Kikuchi, Miho, Itoi, Takao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7872796/
https://www.ncbi.nlm.nih.gov/pubmed/33229812
http://dx.doi.org/10.2169/internalmedicine.6294-20
_version_ 1783649255381008384
author Nagai, Kazumasa
Kitamura, Katsuya
Hirai, Yuji
Nutahara, Daisuke
Nakamura, Hironori
Taira, Junichi
Matsue, Yubu
Abe, Masakazu
Kikuchi, Miho
Itoi, Takao
author_facet Nagai, Kazumasa
Kitamura, Katsuya
Hirai, Yuji
Nutahara, Daisuke
Nakamura, Hironori
Taira, Junichi
Matsue, Yubu
Abe, Masakazu
Kikuchi, Miho
Itoi, Takao
author_sort Nagai, Kazumasa
collection PubMed
description Cancer patients are regarded as highly vulnerable to severe acute respiratory syndrome coronavirus (SARS-CoV)-2. However, little is known regarding how cancer treatments should be restarted for cancer patients after coronavirus disease (COVID)-19. We herein report a pancreatic cancer case in which chemotherapy was able to be reinstituted after COVID-19. The patient was a 67-year-old man diagnosed with pancreatic cancer. On day 7 after first chemotherapy, he was infected with COVID-19. A SARS-CoV-2 test was negative after one month of treatment, and we reinstituted chemotherapy. The patient has received three cycles of chemotherapy without recurrence of COVID-19. It may be feasible to reinstitute chemotherapy for cancer patients after a negative SARS-CoV-2 test.
format Online
Article
Text
id pubmed-7872796
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-78727962021-02-17 Successful and Safe Reinstitution of Chemotherapy for Pancreatic Cancer after COVID-19 Nagai, Kazumasa Kitamura, Katsuya Hirai, Yuji Nutahara, Daisuke Nakamura, Hironori Taira, Junichi Matsue, Yubu Abe, Masakazu Kikuchi, Miho Itoi, Takao Intern Med Case Report Cancer patients are regarded as highly vulnerable to severe acute respiratory syndrome coronavirus (SARS-CoV)-2. However, little is known regarding how cancer treatments should be restarted for cancer patients after coronavirus disease (COVID)-19. We herein report a pancreatic cancer case in which chemotherapy was able to be reinstituted after COVID-19. The patient was a 67-year-old man diagnosed with pancreatic cancer. On day 7 after first chemotherapy, he was infected with COVID-19. A SARS-CoV-2 test was negative after one month of treatment, and we reinstituted chemotherapy. The patient has received three cycles of chemotherapy without recurrence of COVID-19. It may be feasible to reinstitute chemotherapy for cancer patients after a negative SARS-CoV-2 test. The Japanese Society of Internal Medicine 2020-11-23 2021-01-15 /pmc/articles/PMC7872796/ /pubmed/33229812 http://dx.doi.org/10.2169/internalmedicine.6294-20 Text en Copyright © 2021 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Nagai, Kazumasa
Kitamura, Katsuya
Hirai, Yuji
Nutahara, Daisuke
Nakamura, Hironori
Taira, Junichi
Matsue, Yubu
Abe, Masakazu
Kikuchi, Miho
Itoi, Takao
Successful and Safe Reinstitution of Chemotherapy for Pancreatic Cancer after COVID-19
title Successful and Safe Reinstitution of Chemotherapy for Pancreatic Cancer after COVID-19
title_full Successful and Safe Reinstitution of Chemotherapy for Pancreatic Cancer after COVID-19
title_fullStr Successful and Safe Reinstitution of Chemotherapy for Pancreatic Cancer after COVID-19
title_full_unstemmed Successful and Safe Reinstitution of Chemotherapy for Pancreatic Cancer after COVID-19
title_short Successful and Safe Reinstitution of Chemotherapy for Pancreatic Cancer after COVID-19
title_sort successful and safe reinstitution of chemotherapy for pancreatic cancer after covid-19
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7872796/
https://www.ncbi.nlm.nih.gov/pubmed/33229812
http://dx.doi.org/10.2169/internalmedicine.6294-20
work_keys_str_mv AT nagaikazumasa successfulandsafereinstitutionofchemotherapyforpancreaticcanceraftercovid19
AT kitamurakatsuya successfulandsafereinstitutionofchemotherapyforpancreaticcanceraftercovid19
AT hiraiyuji successfulandsafereinstitutionofchemotherapyforpancreaticcanceraftercovid19
AT nutaharadaisuke successfulandsafereinstitutionofchemotherapyforpancreaticcanceraftercovid19
AT nakamurahironori successfulandsafereinstitutionofchemotherapyforpancreaticcanceraftercovid19
AT tairajunichi successfulandsafereinstitutionofchemotherapyforpancreaticcanceraftercovid19
AT matsueyubu successfulandsafereinstitutionofchemotherapyforpancreaticcanceraftercovid19
AT abemasakazu successfulandsafereinstitutionofchemotherapyforpancreaticcanceraftercovid19
AT kikuchimiho successfulandsafereinstitutionofchemotherapyforpancreaticcanceraftercovid19
AT itoitakao successfulandsafereinstitutionofchemotherapyforpancreaticcanceraftercovid19

Ejemplares similares